Protein / target
Transforming growth factor beta-3 proprotein
Protein at a glance
Biological role
Type III transforming growth factor beta receptor binding
Strongest disease association
Pulmonary Emphysema
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Transforming growth factor beta-3 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-3 (TGF-beta-3) chains, which constitute the regulatory and active subunit of TGF-beta-3, respectively
Subcellular location
Domains and Gene Ontology detail (44)Hide
Gene Ontology
- Cextracellular matrix
- Cextracellular region
- Cextracellular space
- Cplasma membrane
- Cplatelet alpha granule lumen
- Ctransforming growth factor beta complex
- Fcytokine activity
- Fgrowth factor activity
- Fidentical protein binding
- Ftransforming growth factor beta binding
- Ftype I transforming growth factor beta receptor binding
- Ftype II transforming growth factor beta receptor binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·negative regulation of cell population proliferation
- ·positive regulation of cell population proliferation
- ·regulation of cell population proliferation
Cell adhesion
- ·Secreted, extracellular space, extracellular matrix
- ·extracellular matrix
- ·cell-cell junction organization
- ·positive regulation of tight junction disassembly
Immune signalling
- ·cytokine activity
- ·negative regulation of macrophage cytokine production
Transcriptional regulation
- ·positive regulation of DNA-templated transcription
- ·positive regulation of transcription by RNA polymerase II
Apoptosis & cell death
- ·negative regulation of neuron apoptotic process
- ·positive regulation of apoptotic process
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Transforming growth factor beta inhibitor
Indicated for Anemia, beta-Thalassemia, Myelodysplastic Syndromes
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene TGFB3
Gene-level evidence surfaced through the gene TGFB3 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (2)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
3 compounds recorded · 1 approved · 2 in clinical development
View all recorded compounds (3)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Antibodies — Strong
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (6)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Regulatory approval
Approval: Reblozyl (EMA)
- New publicationLuspatercept in Myelodysplastic Syndromes: Who and When?
- New publicationLuspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
- New publicationLuspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
- New publicationLuspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.